|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics. CA Cancer J Clin. 57:43–66.
2007.
|
|
2
|
Clark TG, Stewart ME, Altman DG, Gabra H
and Smyth JF: A prognostic model for ovarian cancer. Br J Cancer.
85:944–952. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baylin SB and Herman JG: DNA methylation
in tumorigenesis: epigenetics joins genetics. Trends Genet.
16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jones PA: DNA methylation errors and
cancer. Cancer Res. 56:2463–2467. 1996.PubMed/NCBI
|
|
5
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson AS, Power BE and Molloy PL: DNA
hypomethylation and human diseases. Biochem Biophys Acta.
1775:138–162. 2007.PubMed/NCBI
|
|
7
|
Jones PA: The DNA methylation paradox.
Trends Genet. 15:34–37. 1999. View Article : Google Scholar
|
|
8
|
Lund AH and van Lohuizen M: Epigenetics
and cancer. Genes Dev. 18:2315–2335. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laird PW: Cancer epigenetics. Hum Mol
Genet. 14:R65–R76. 2005. View Article : Google Scholar
|
|
10
|
Ducasse M and Brown MA: Epigenetic
aberrations and cancer. Mol Cancer. 5:602006. View Article : Google Scholar
|
|
11
|
Paluszczak J and Baer-Dubowska W:
Epigenetic diagnostics of cancer - the application of DNA
methylation markers. J Appl Genet. 47:365–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barton CA, Hacker NF, Clark SJ and O’Brien
PM: DNA methylation changes in ovarian cancer: implications for
early diagnosis, prognosis and treatment. Gynecol Oncol.
109:129–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Swisher EM, Gonzalez RM, Taniguchi T,
Garcia RL, Walsh T, Goff BA and Welcsh P: Methylation and protein
expression of DNA repair genes: association with chemotherapy
exposure and survival in sporadic ovarian and peritoneal
carcinomas. Mol Cancer. 8:482009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ibanez de Caceres I, Battagli C, Esteller
M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg
BL and Cairns P: Tumor cell-specific BRCA1 and RASSF1A
hyper-methylation in serum, plasma and peritoneal fluid from
ovarian cancer patients. Cancer Res. 64:6476–6481. 2004.PubMed/NCBI
|
|
15
|
Makarla PB, Saboorian MH, Ashfaq R,
Toyooka KO, Toyooka S, Minna JD, Gazdar AF and Schorge JO: Promoter
hypermethylation profile of ovarian epithelial neoplasms. Clin
Cancer Res. 11:5365–5369. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rathi A, Virmani AK, Schorge JO, Elias KJ,
Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA and Gazdar AF:
Methylation profiles of sporadic ovarian tumors and nonmalignant
ovaries from high-risk women. Clin Cancer Res. 8:3324–3331.
2002.PubMed/NCBI
|
|
17
|
Yuecheng Y, Hongmei L and Xiaoyan X:
Clinical evaluation of E-cadherin expression and its regulation
mechanism in epithelial ovarian cancer. Clin Exp Metastasis.
23:65–74. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tam KF, Liu VW, Liu SS, Tsang PC, Cheung
AN, Yip AM and Ngan HY: Methylation profile in benign, borderline
and malignant ovarian tumors. J Cancer Res Clin Oncol. 133:331–341.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strathdee G, Appleton K, Illand M, Millan
DW, Sargent J, Paul J and Brown R: Primary ovarian carcinomas
display multiple methylator phenotypes involving known tumor
suppressor genes. Am J Pathol. 158:1121–1127. 2001. View Article : Google Scholar
|
|
20
|
Kiwerska K, Rydzanicz M, Kram A, Pastok M,
Antkowiak A, Domagala W and Szyfter K: Mutational analysis of
CDKN2A gene in a group of 390 larynx cancer patients. Mol Biol Rep.
37:325–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Costello JF, Frühwald MC, Smiraglia DJ,
Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P,
Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A,
Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O’Dorisio MS, Held
WA, Cavenee WK and Plass C: Aberrant CpG-island methylation has
non-random and tumour-type-specific patterns. Nat Genet.
24:132–138. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mehrotra J, Ganpat MM, Kanan Y, Fackler
MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T,
Garrett E, Parmigiani G, Broome C and Sukumar S: Estrogen
receptor/progesterone receptor-negative breast cancers of young
African-American women have a higher frequency of methylation of
multiple genes than those of Caucasian women. Clin Cancer Res.
10:2052–2057. 2004. View Article : Google Scholar
|
|
23
|
Nygren AO, Ameziane N, Duarte HM,
Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP and Errami A:
Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG
methylation and copy number changes of up to 40 sequences. Nucleic
Acids Res. 33:e1282005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Warnecke PM and Bestor TH: Cytosine
methylation and human cancer. Curr Opin Oncol. 12:68–73. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El-Osta A, Baker EK and Wolffe AP:
Profiling methyl-CpG specific determinants on transcriptionally
silent chromatin. Mol Biol Rep. 28:209–215. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
27
|
Esteller M, Corn PG, Baylin SB and Herman
JG: A gene hyper-methylation profile of human cancer. Cancer Res.
61:3225–3229. 2001.PubMed/NCBI
|
|
28
|
Sellar GC, Watt KP, Rabiasz GJ, Stronach
EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B,
Scott D, Brown I, Williams AR, Bates PA, Smyth JF and Garba H:
OPCML at 11q25 is epigenetically inactivated and has
tumor-suppressor function in epithelial ovarian cancer. Nat Genet.
34:337–343. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Teodoridis JM, Hall J, Marsh S, Kannall
HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G
and Brown R: CpG island methylation of DNA damage response genes in
advanced ovarian cancer. Cancer Res. 65:8961–8967. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wakana K, Akiyama Y, Aso T and Yuasa Y:
Involvement of GATA-4/5 transcription factors in ovarian
carcinogenesis. Cancer Lett. 241:281–288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Milde-Langosch K, Ocon E, Becker G and
Löning T: p16/MTS1 inactivation in ovarian carcinomas: high
frequency of reduced protein expression associated with
hyper-methylation or mutation in endometrioid and mucinous tumors.
Int J Cancer. 79:61–65. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kudoh K, Ichikawa Y, Yoshida S, Hirai M,
Kikuchi Y, Nagata I, Miwa M and Uchida K: Inactivation of p16/CDKN2
and p15/MTS2 is associated with prognosis and response to
chemotherapy in ovarian cancer. Int J Cancer. 99:579–582. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schildkraut JM, Moorman PG, Bland AE,
Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T,
Bentley RC, Marks JR and Berchuck A: Cyclin E overexpression in
epithelial ovarian cancer characterizes an etiologic subgroup.
Cancer Epidemiol Biomarkers Prev. 17:585–593. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim
J, Cho SH and An HJ: Significance of cell cycle regulatory proteins
as malignant and prognostic biomarkers in ovarian epithelial
tumors. Int J Gynecol Pathol. 30:205–217. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Drexler HG: Review of alterations of the
cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18
and p19 in human leukemia-lymphoma cells. Leukemia. 12:845–859.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan
HY: Differential DNA methylation profiles in gynecological cancers
and correlation with clinico-pathological data. BMC Cancer.
6:2122006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fujita M, Enomoto T, Haba T, Nakashima R,
Sasaki M, Yoshino K, Wada H, Buzard GS, Matsuzaki N, Wakasa K and
Murata Y: Alteration of p16 and p15 genes in common epithelial
ovarian tumors. Int J Cancer. 74:148–155. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dodge JE, Munson C and List AF: KG-1 and
KG-1a model the p15 CpG island methylation observed in acute
myeloid leukemia patients. Leukemia Res. 25:917–925. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Aggerholm A, Guldberg P, Hokland M and
Hokland P: Extensive intra- and interindividual heterogeneity of
p15INK4B methylation in acute myeloid leukemia. Cancer Res.
59:436–441. 1999.PubMed/NCBI
|
|
40
|
Herman JG, Jen J, Merlo A and Baylin SB:
Hypermethylation-associated inactivation indicates a tumor
suppressor role for p15INK4B. Cancer Res. 56:722–727.
1996.PubMed/NCBI
|
|
41
|
Wang Y, Zhang D, Zheng W, Luo J, Bai Y and
Lu Z: Multiple gene methylation of nonsmall cell lung cancers
evaluated with 3-dimensional microarray. Cancer. 112:1325–1336.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Buyru N, Altinisik J, Ozdemir F, Demokan S
and Dalay N: Methylation profiles in breast cancer. Cancer Invest.
27:307–312. 2009. View Article : Google Scholar
|
|
43
|
Liu Z, Wang LE, Wang L, Lu KH, Mills GB,
Bondy ML and Wei Q: Methylation and messenger RNA expression of
p15INK4b but not p16INK4a are independent risk factors for ovarian
cancer. Clin Cancer Res. 11:4968–4976. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kawakami M, Staub J, Cliby W, Hartmann L,
Smith DI and Shridhar V: Involvement of H-cadherin (CDH13) on 16q
in the region of frequent deletion in ovarian cancer. Int J Oncol.
15:715–720. 1999.PubMed/NCBI
|
|
45
|
Toyooka KO, Toyooka S, Virmani AK,
Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF:
Loss of expression and aberrant methylation of the CDH13
(H-cadherin) gene in breast and lung carcinomas. Cancer Res.
61:4556–4560. 2001.PubMed/NCBI
|
|
46
|
Wu Q, Lothe RA, Ahlquist T, Silins I,
Tropé CG, Micci F, Nesland JM, Suo Z and Lind GE: DNA methylation
profiling of ovarian carcinomas and their in vitro models
identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol
Cancer. 6:452007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dammann R, Schagdarsurengin U, Seidal C,
Strunnikova M, Rastetter M, Baier K and Pfeifer GP: The tumor
suppressor RASSF1A in human carcinogenesis: an update. Histol
Histopathol. 20:645–663. 2005.PubMed/NCBI
|
|
48
|
Yoon JH, Dammann R and Pfeifer GP:
Hypermethylation of the CpG island of RASSF1A gene in ovarian and
renal cell carcinomas. Int J Cancer. 94:212–217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Agathanggelou A, Honorio S, Macartney DP,
Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R,
Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F:
Methylation associated inactivation of RASSF1A from region 3p21.3
in lung, breast and ovarian tumors. Oncogene. 20:1509–1518. 2001.
View Article : Google Scholar : PubMed/NCBI
|
